Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as […]readmore
Tags : #EULAR
Shots: Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg, qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study […]readmore
Shots: The P-III SELECT EARLY & SELECT-COMPARE study results involve assessing of Upadacitinib (15mg/30mg,qd) as monothx. & Upadacitinib + MTX (15mg, qd) vs MTX & adalimumab + MTX in patients […]readmore